Precision medicine has been gaining ground in recent years with moves by physicians to order more genetic tests to understand how a particular patient’s malady – especially in the field of oncology – may be treated. Payers, including Medicare, are also beginning to cover next-generation sequencing tests. Aside from life science companies, the success of precision medicine also hinges on data analytics companies and software companies.
Chicago-based CancerIQ is one such firm. As we focus on discussing various aspects of precision medicine as part of our virtual INVEST Precision Medicine Conference, Dec.9-11, we thought to spotlight Cancer IQ and its founder and CEO, Feyi Olopade Ayodele. Designed to integrate easily into the clinical workflow, the CancerIQ platforms helps providers identify, evaluate and manage populations based on genetic risk factors while also enabling virtual visits. Click below to learn more.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Photo: Adam Taylor, Getty Images
